February 22, 2022 -- Remix Therapeutics is collaborating with Janssen Pharmaceutica, one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
The agreement was facilitated by Johnson & Johnson Innovation. Under the terms of the agreement, Remix will receive an initial payment of $45 million in cash for upfront and research funding. It may also receive preclinical, clinical, commercial, and sales milestone payments and tiered royalties for any resulting products. In exchange, Janssen will have exclusive rights to three specific targets with applications in immunology and oncology.
Remix will have the ability to opt into a portion of the costs of clinical development on one program in exchange for higher royalties. Under the agreement, Remix is eligible to receive total payments potentially exceeding $1 billion, subject to regulatory approvals and other conditions.
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in new ways.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
